[HTML][HTML] Structural biology of SARS-CoV-2: open the door for novel therapies

W Yan, Y Zheng, X Zeng, B He, W Cheng - Signal Transduction and …, 2022 - nature.com
Abstract Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is the causative
agent of the pandemic disease COVID-19, which is so far without efficacious treatment. The …

[HTML][HTML] The signal pathways and treatment of cytokine storm in COVID-19

L Yang, X Xie, Z Tu, J Fu, D Xu, Y Zhou - Signal transduction and …, 2021 - nature.com
Abstract The Coronavirus Disease 2019 (COVID-19) pandemic has become a global crisis
and is more devastating than any other previous infectious disease. It has affected a …

COVID-19 therapeutics: Challenges and directions for the future

PC Robinson, DFL Liew, HL Tanner… - Proceedings of the …, 2022 - National Acad Sciences
The emergence of SARS-CoV-2 triggering the COVID-19 pandemic ranks as arguably the
greatest medical emergency of the last century. COVID-19 has highlighted health disparities …

[HTML][HTML] Aging, immunity, and COVID-19: how age influences the host immune response to coronavirus infections?

V Bajaj, N Gadi, AP Spihlman, SC Wu, CH Choi… - Frontiers in …, 2021 - frontiersin.org
The novel coronavirus severe acute respiratory syndrome coronavirus 2 causing the
Coronavirus disease (COVID-19) pandemic has ravaged the world with over 72 million total …

[HTML][HTML] Immunity, endothelial injury and complement-induced coagulopathy in COVID-19

L Perico, A Benigni, F Casiraghi, LFP Ng… - Nature Reviews …, 2021 - nature.com
In December 2019, a novel coronavirus was isolated from the respiratory epithelium of
patients with unexplained pneumonia in Wuhan, China. This pathogen, named severe acute …

Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis

JAC Sterne, S Murthy, JV Diaz, AS Slutsky, J Villar… - Jama, 2020 - jamanetwork.com
Importance Effective therapies for patients with coronavirus disease 2019 (COVID-19) are
needed, and clinical trial data have demonstrated that low-dose dexamethasone reduced …

[HTML][HTML] COVID-19 in early 2021: current status and looking forward

C Wang, Z Wang, G Wang, JYN Lau… - Signal Transduction and …, 2021 - nature.com
Since the first description of a coronavirus-related pneumonia outbreak in December 2019,
the virus SARS-CoV-2 that causes the infection/disease (COVID-19) has evolved into a …

Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial

DC Angus, L Derde, F Al-Beidh, D Annane, Y Arabi… - Jama, 2020 - jamanetwork.com
Importance Evidence regarding corticosteroid use for severe coronavirus disease 2019
(COVID-19) is limited. Objective To determine whether hydrocortisone improves outcome for …

The cytokine storm and COVID‐19

B Hu, S Huang, L Yin - Journal of medical virology, 2021 - Wiley Online Library
Abstract Coronavirus disease 2019 (COVID‐19), which began in Wuhan, China, in
December 2019, has caused a large global pandemic and poses a serious threat to public …

[HTML][HTML] Cytokine storm in COVID-19: the current evidence and treatment strategies

Y Tang, J Liu, D Zhang, Z Xu, J Ji, C Wen - Frontiers in immunology, 2020 - frontiersin.org
Severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) is the pathogen that causes
coronavirus disease 2019 (COVID-19). As of 25 May 2020, the outbreak of COVID-19 has …